Alnylam Pharmaceuticals (ALNY) Stock: Gaining On Planned Phase III Trial
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is having a pretty strong start to the trading session today, and for good reason. The company announced that it has reached an agreement with the FDA surrounding a planned Phase III clinical trial. As a result, investors got excited and the stock is finding its way upward. As is … Read more